Santarus Stock Hits New 52-Week High (SNTS)

NEW YORK ( TheStreet) -- Santarus (Nasdaq: SNTS) hit a new 52-week high Thursday as it is currently trading at $24.46, above its previous 52-week high of $24.43 with 1.4 million shares traded as of 2:05 p.m. ET. Average volume has been 1.4 million shares over the past 30 days.

Santarus has a market cap of $1.51 billion and is part of the health care sector and drugs industry. Shares are up 112.5% year to date as of the close of trading on Wednesday.

Santarus, Inc., a specialty biopharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that address the needs of patients treated by physician specialists.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Santarus as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. You can view the full Santarus Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..
null

If you liked this article you might like

Investors Expect too Much of Salix

The Deal: Salix Pharmaceuticals Buys Santarus for $2.6B

Santarus (SNTS): Heavy Pre-Market Activity

Salix Pharma to Acquire Santarus

Insider Trading Alert - Santarus And 4 Others Traded By Insiders